Sartorius Stedim Biotech: 2022 results still strong

(CercleFinance.com) - Sartorius Stedim Biotech shares are steaming ahead, up almost 8% in Paris, after the publication of its preliminary results for FY 2022, which were still considered solid.


The biopharmaceutical supplier's revenues reached 3.49 billion euros last year, representing organic growth of 13.2% at constant exchange rates.

Including acquisitions, growth reached 15.1%.

Underlying Ebitda was 1.22 billion euros, compared with 1.03 billion euros in 2021, meaning a margin of 35%, down from the 35.8% announced at end-2021.

After two "exceptional" years due to the pandemic, Sartorius Stedim reports a "normalisation" of demand, in line with its forecasts.

For 2023, the company expects low to mid-single digit sales growth and in the mid- to high-single digits without taking into account the Covid-19 pandemic-related activities.

Its underlying Ebitda margin is expected to be approximately the same level as the previous year given the still significant uncertainties surrounding the global political and economic situation.


Copyright (c) 2023 CercleFinance.com. All rights reserved.